Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study of RAD001 in Patients With Recurrent Endometrial Cancer.

Trial Profile

A Phase II Study of RAD001 in Patients With Recurrent Endometrial Cancer.

Phase of Trial: Phase II

Latest Information Update: 11 Feb 2016

At a glance

  • Drugs Everolimus (Primary)
  • Indications Endometrial cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jan 2015 The primary endpoint has been changed from RAD001 can shrink or slow the growth of tumors to objective response plus stable disease rate along with change in assessment duration from 4 years to 8 weeks as per ClinicalTrials.gov record.
    • 07 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 03 Feb 2014 Planned End Date changed from 1 Jun 2014 to 1 Jun 2015 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top